BioVeris and U.S. Army Enter Into R&D Agreement
Wednesday January 5, 9:15 am ET
GAITHERSBURG, MD, Jan. 5 /PRNewswire-FirstCall/ -- BioVeris Corporation (Nasdaq: BIOV - News) and the Brooke Army Medical Center, Department of Clinical Investigation have entered into a Cooperative Research and Development Agreement (CRADA) to develop BioVeris Technology(TM)-based tests for the detection of clinical markers of disease and disease progression or recovery. Work under the CRADA will occur over the next two years. BioVeris will be able to commercialize tests of clinical significance that may be identified. The CRADA is expected to provide research experience for the medical residents of the teaching program at Brooke Army Medical Center.
Diagnosis of disease is frequently based on the detection of specific markers of a disease state. Using conventional methods, the design of tests for the detection of these clinical markers often has sensitivity and specificity limitations. BioVeris (BV) Technology-based systems currently sold commercially for the detection of markers of potential bioterror agents, such as botulinum neurotoxin, ricin and staphylococcal enterotoxins, have demonstrated a potential for rapid, specific and sensitive tests. The tests expected to be developed under the CRADA will explore numerous clinical markers to improve patient diagnosis and monitoring for the military community and the public. In addition, future patients at Brooke Army Medical Center may be able to receive more rapid diagnoses of disease and improved monitoring of the progression or recovery from disease.
The Department of Clinical Investigation (DCI) is a research facility attached to Brooke Army Medical Center at Fort Sam Houston, Texas, the home of the Combat Medic. The DCI provides comprehensive services for biomedical research, supporting both basic and clinical research. <snip> |
